Anti-Human CD40 (Clone HB-14) – Purified in vivo GOLDTM Functional Grade

Anti-Human CD40 (Clone HB-14) – Purified in vivo GOLDTM Functional Grade

Product No.: C1030

- -
- -
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
Mouse IgG1 κ

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Host Species
Recombinant protein of CD40 protein
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
≥95% by SDS Page
≥95% monomer by analytical SEC
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
2-8°C Wet Ice
Additional Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


Clone HB-14 recognizes human CD40.
CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) - a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen-presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation, and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy; blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific to human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus playing a significant part in Alzheimer's disease pathogenesis.

The anti-CD40 HB-14 clone was generated as part of a panel submitted to the Fifth International Leukocyte Differentiation Antigen Workshop1.
Antigen Distribution
CD40 is widely expressed on antigen-presenting cells such as dendritic cells, B cells, macrophages, and monocytes, in addition to non-immune endothelial cells, basal epithelial cells, and a variety of tumors.

Antigen Details

CD154 (CD40 ligand)
NCBI Gene Bank ID
Research Area
Cell Biology
Costimulatory Molecules

References & Citations

1. Katira A, Holder MJ, Pound JD, and Gordon J. 1995. CD40 Workshop Panel Report. In Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF, and Todd RF, eds, Leukocyte Typing V, p. 547. Oxford University Press, Oxford.
2. Herbert J. Thesis: The regulation of specific antibody secretion by human B cells through contact and non-contact dependent mechanisms. 1996.
3. Zhou LJ, Tedder TF. Proc Natl Acad Sci U S A. 93(6):2588-2592. 1996.
4. Tan PH, Beutelspacher SC, Xue SA, et al. Blood. 105(10):3824-3832. 2005.
5. Iwata Y, Matsushita T, Horikawa M, et al. Blood. 117(2):530-541. 2011.
6. Bacher P, Schink C, Teutschbein J, et al. J Immunol. 190(8):3967-3976. 2013.
7. Bacher P, Heinrich F, Stervbo U, et al. Cell. 167(4):1067-1078.e16. 2016.
8. Mura M, Chaudhury S, Farooq F, et al. MethodsX. 22;7:101005. 2020.
9. Pound JD, Challa A, Holder MJ, et al. Int Immunol. 11(1):11-20. 1999.
Flow Cytometry

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.